
<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>Dzugg / Published News / WeightLoss</title>
<link>http://www.Dzugg.com</link>
<description>Dzugg is a social bookmarking and blogging site  votes</description>
<pubDate>Wed, 03 Dec 2008 21:59:48 PST</pubDate>
<language>en</language>
<item>
<title><![CDATA[Business newsmaker - Toronto Star]]></title>
<link>http://www.Dzugg.com/WeightLoss/Business_newsmaker_-_Toronto_Star/</link>
<comments>http://www.Dzugg.com/WeightLoss/Business_newsmaker_-_Toronto_Star/</comments>
<pubDate>Wed, 03 Dec 2008 21:59:48 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Business_newsmaker_-_Toronto_Star/</guid>
<description><![CDATA[Business newsmakerToronto Star,&amp;nbsp; Canada&amp;nbsp;- Dec 2, 2008Viehbacher takes over from scientist Gerard le Fur, who was ousted in September after setbacks with the Acomplia obesity pill and the Plavix blood thinne<br/><br/>101 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer, Sanofi-Avensis End Studies on Diet Drugs - eFluxMedia]]></title>
<link>http://www.Dzugg.com/WeightLoss/Pfizer_Sanofi-Avensis_End_Studies_on_Diet_Drugs_-_eFluxMedia/</link>
<comments>http://www.Dzugg.com/WeightLoss/Pfizer_Sanofi-Avensis_End_Studies_on_Diet_Drugs_-_eFluxMedia/</comments>
<pubDate>Wed, 03 Dec 2008 21:59:38 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Pfizer_Sanofi-Avensis_End_Studies_on_Diet_Drugs_-_eFluxMedia/</guid>
<description><![CDATA[Pfizer, Sanofi-Avensis End Studies on Diet DrugseFluxMedia&amp;nbsp;- Nov 7, 2008Sanofi-Aventis suspended European sales of its CB-1 antagonist, Acomplia after European regulators said the drug should be withdrawn from t<br/><br/>101 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[New Sanofi CEO Expected to Map Fresh Course on Developing Drugs - Wall Street Journal]]></title>
<link>http://www.Dzugg.com/WeightLoss/New_Sanofi_CEO_Expected_to_Map_Fresh_Course_on_Developing_Drugs_-_Wall_Street_Journal/</link>
<comments>http://www.Dzugg.com/WeightLoss/New_Sanofi_CEO_Expected_to_Map_Fresh_Course_on_Developing_Drugs_-_Wall_Street_Journal/</comments>
<pubDate>Mon, 01 Dec 2008 03:29:14 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/New_Sanofi_CEO_Expected_to_Map_Fresh_Course_on_Developing_Drugs_-_Wall_Street_Journal/</guid>
<description><![CDATA[New Sanofi CEO Expected to Map Fresh  Course on Developing DrugsWall Street Journal&amp;nbsp;- 6 hours agoOne example: the obesity pill Acomplia, which Sanofi continued to develop years after signs emerged that the drug <br/><br/>101 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Development of rimonabant and CP-945598 for obesity is discontinued - Drug Topics Magazine]]></title>
<link>http://www.Dzugg.com/WeightLoss/Development_of_rimonabant_and_CP-945598_for_obesity_is_discontinued_-_Drug_Topics_Magazine/</link>
<comments>http://www.Dzugg.com/WeightLoss/Development_of_rimonabant_and_CP-945598_for_obesity_is_discontinued_-_Drug_Topics_Magazine/</comments>
<pubDate>Mon, 01 Dec 2008 03:29:10 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Development_of_rimonabant_and_CP-945598_for_obesity_is_discontinued_-_Drug_Topics_Magazine/</guid>
<description><![CDATA[Development of rimonabant and CP-945598 for obesity is discontinuedDrug Topics Magazine,&amp;nbsp;NJ&amp;nbsp;- Nov 13, 2008... European marketing authorization of rimonabant (European brand name Acomplia) be suspended becau<br/><br/>101 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Growth hormone not beneficial for ALS]]></title>
<link>http://www.Dzugg.com/WeightLoss/Growth_hormone_not_beneficial_for_ALS/</link>
<comments>http://www.Dzugg.com/WeightLoss/Growth_hormone_not_beneficial_for_ALS/</comments>
<pubDate>Sat, 29 Nov 2008 04:04:10 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Growth_hormone_not_beneficial_for_ALS/</guid>
<description><![CDATA[ST. PAUL, Minn., Nov. 24, 2008&amp;nbsp;&amp;ndash; A growth hormone that had shown some promise for treating people with amyotrophic lateral sclerosis (ALS) showed no benefit in a new study published in the November 25, 2008, issue of Neurology, the...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease]]></title>
<link>http://www.Dzugg.com/WeightLoss/Ceregene_Announces_Clinical_Data_From_Phase_2_Clinical_Trial_of_CERE-120_for_Parkinsons_Disease/</link>
<comments>http://www.Dzugg.com/WeightLoss/Ceregene_Announces_Clinical_Data_From_Phase_2_Clinical_Trial_of_CERE-120_for_Parkinsons_Disease/</comments>
<pubDate>Sat, 29 Nov 2008 04:03:17 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Ceregene_Announces_Clinical_Data_From_Phase_2_Clinical_Trial_of_CERE-120_for_Parkinsons_Disease/</guid>
<description><![CDATA[SAN DIEGO, November 26, 2008 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, today reported clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease. The trial did not...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer's Novel HIV/AIDS Treatment Selzentry Becomes the Latest Fully Approved Antiretrovial for Treatment-Experienced HIV Patients]]></title>
<link>http://www.Dzugg.com/WeightLoss/Pfizers_Novel_HIVAIDS_Treatment_Selzentry_Becomes_the_Latest_Fully_Approved_Antiretrovial_for_Treatment-Experienced_HIV_Patients/</link>
<comments>http://www.Dzugg.com/WeightLoss/Pfizers_Novel_HIVAIDS_Treatment_Selzentry_Becomes_the_Latest_Fully_Approved_Antiretrovial_for_Treatment-Experienced_HIV_Patients/</comments>
<pubDate>Sat, 29 Nov 2008 04:02:38 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Pfizers_Novel_HIVAIDS_Treatment_Selzentry_Becomes_the_Latest_Fully_Approved_Antiretrovial_for_Treatment-Experienced_HIV_Patients/</guid>
<description><![CDATA[NEW YORK--(BUSINESS WIRE)--Nov 25, 2008 - The U.S. Food and Drug Administration (FDA) has granted SELZENTRY&amp;trade; (maraviroc) full (traditional) approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections]]></title>
<link>http://www.Dzugg.com/WeightLoss/FDA_Issues_Complete_Response_Letter_for_Ceftobiprole_for_Treatment_of_Complicated_Skin_Infections/</link>
<comments>http://www.Dzugg.com/WeightLoss/FDA_Issues_Complete_Response_Letter_for_Ceftobiprole_for_Treatment_of_Complicated_Skin_Infections/</comments>
<pubDate>Sat, 29 Nov 2008 04:02:10 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/FDA_Issues_Complete_Response_Letter_for_Ceftobiprole_for_Treatment_of_Complicated_Skin_Infections/</guid>
<description><![CDATA[RARITAN, N.J., November 26, 2008 /PRNewswire/ -- Johnson &amp;amp; Johnson Pharmaceutical Research &amp;amp; Development, L.L.C. (J&amp;amp;JPRD), today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA)...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Use Of Inhaled Corticosteroids For Copd Does Not Appear To Improve Survival, But May Increase Risk For Pneumonia]]></title>
<link>http://www.Dzugg.com/WeightLoss/Use_Of_Inhaled_Corticosteroids_For_Copd_Does_Not_Appear_To_Improve_Survival_But_May_Increase_Risk_For_Pneumonia/</link>
<comments>http://www.Dzugg.com/WeightLoss/Use_Of_Inhaled_Corticosteroids_For_Copd_Does_Not_Appear_To_Improve_Survival_But_May_Increase_Risk_For_Pneumonia/</comments>
<pubDate>Sat, 29 Nov 2008 04:01:29 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Use_Of_Inhaled_Corticosteroids_For_Copd_Does_Not_Appear_To_Improve_Survival_But_May_Increase_Risk_For_Pneumonia/</guid>
<description><![CDATA[CHICAGO, Nov. 25, 2008&amp;mdash;An analysis of randomized trials indicates that use of inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease (COPD) does not improve the rate of survival after one year, but is associated...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA Sends Warning Letter to Actelion Over Tracleer Flash Card]]></title>
<link>http://www.Dzugg.com/WeightLoss/FDA_Sends_Warning_Letter_to_Actelion_Over_Tracleer_Flash_Card/</link>
<comments>http://www.Dzugg.com/WeightLoss/FDA_Sends_Warning_Letter_to_Actelion_Over_Tracleer_Flash_Card/</comments>
<pubDate>Sat, 29 Nov 2008 04:00:20 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/FDA_Sends_Warning_Letter_to_Actelion_Over_Tracleer_Flash_Card/</guid>
<description><![CDATA[ROCKVILLE, Md., Nov. 25, 2008-Today the Food and Drug Administration posted&amp;nbsp;on its website a warning letter&amp;nbsp;sent to Actelion Pharmaceuticals regarding&amp;nbsp;a Sildenafil Flash Card&amp;nbsp;for Tracleer (bosentan) tablets. The letter is...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Analysts: Look for shake-up at Sanofi - FierceBiotech]]></title>
<link>http://www.Dzugg.com/WeightLoss/Analysts_Look_for_shake-up_at_Sanofi_-_FierceBiotech/</link>
<comments>http://www.Dzugg.com/WeightLoss/Analysts_Look_for_shake-up_at_Sanofi_-_FierceBiotech/</comments>
<pubDate>Sat, 29 Nov 2008 03:00:44 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Analysts_Look_for_shake-up_at_Sanofi_-_FierceBiotech/</guid>
<description><![CDATA[Analysts: Look for shake-up at SanofiFierceBiotech,&amp;nbsp;DC&amp;nbsp;- Nov 3, 2008... the company cope with a number of challenges, including  patent expirations, the withdraw of Acomplia in Europe, and several failed cl<br/><br/>101 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Vicar tells of diet drug hell - Lancashire Evening Post]]></title>
<link>http://www.Dzugg.com/WeightLoss/Vicar_tells_of_diet_drug_hell_-_Lancashire_Evening_Post/</link>
<comments>http://www.Dzugg.com/WeightLoss/Vicar_tells_of_diet_drug_hell_-_Lancashire_Evening_Post/</comments>
<pubDate>Fri, 28 Nov 2008 10:06:51 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Vicar_tells_of_diet_drug_hell_-_Lancashire_Evening_Post/</guid>
<description><![CDATA[Vicar tells of diet drug hellLancashire Evening Post,&amp;nbsp;UK&amp;nbsp;- Nov 5, 2008Father Timothy Lipscomb took the anti-obesity drug Rimonabant, also known as Acomplia, for two weeks. But the Vicar of Preston stopped t<br/><br/>101 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bayer Healthcare llc Reaches Settlement with U.S. Department of Justice on Investigation into former Diabetes Care Marketing Programs]]></title>
<link>http://www.Dzugg.com/WeightLoss/Bayer_Healthcare_llc_Reaches_Settlement_with_U-S-_Department_of_Justice_on_Investigation_into_former_Diabetes_Care_Marketing_Programs/</link>
<comments>http://www.Dzugg.com/WeightLoss/Bayer_Healthcare_llc_Reaches_Settlement_with_U-S-_Department_of_Justice_on_Investigation_into_former_Diabetes_Care_Marketing_Programs/</comments>
<pubDate>Fri, 28 Nov 2008 02:53:04 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Bayer_Healthcare_llc_Reaches_Settlement_with_U-S-_Department_of_Justice_on_Investigation_into_former_Diabetes_Care_Marketing_Programs/</guid>
<description><![CDATA[Corporate Integrity Agreement to cover Bayer HealthCare Diabetes Care, Bayer HealthCare Pharmaceuticals, Medrad (including Possis), Intendis and Viterion TeleHealthcare&amp;nbsp;&amp;nbsp;TARRYTOWN, NY (November 25, 2008) &amp;ndash; Bayer Hea<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bayer Healthcare to Pay U.S. $97.5 Million to Settle Allegations of Paying Kickbacks to Diabetic Suppliers]]></title>
<link>http://www.Dzugg.com/WeightLoss/Bayer_Healthcare_to_Pay_U-S-_97-5_Million_to_Settle_Allegations_of_Paying_Kickbacks_to_Diabetic_Suppliers/</link>
<comments>http://www.Dzugg.com/WeightLoss/Bayer_Healthcare_to_Pay_U-S-_97-5_Million_to_Settle_Allegations_of_Paying_Kickbacks_to_Diabetic_Suppliers/</comments>
<pubDate>Fri, 28 Nov 2008 02:51:18 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Bayer_Healthcare_to_Pay_U-S-_97-5_Million_to_Settle_Allegations_of_Paying_Kickbacks_to_Diabetic_Suppliers/</guid>
<description><![CDATA[WASHINGTON, November 25, 2008 /PRNewswire-USNewswire/ -- Bayer HealthCare LLC (Bayer) has agreed to pay the United States $97.5 million plus interest to settle allegations that it paid kickbacks to a number of diabetic suppliers and caused those...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Anika Therapeutics Terminates Contract with U.S. Distribution Partner for ELEVESS]]></title>
<link>http://www.Dzugg.com/WeightLoss/Anika_Therapeutics_Terminates_Contract_with_U-S-_Distribution_Partner_for_ELEVESS/</link>
<comments>http://www.Dzugg.com/WeightLoss/Anika_Therapeutics_Terminates_Contract_with_U-S-_Distribution_Partner_for_ELEVESS/</comments>
<pubDate>Fri, 28 Nov 2008 02:50:35 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Anika_Therapeutics_Terminates_Contract_with_U-S-_Distribution_Partner_for_ELEVESS/</guid>
<description><![CDATA[BEDFORD, Mass.--(BUSINESS WIRE)--Nov 25, 2008 - Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (&amp;ldquo;HA&amp;rdquo;) technology, has terminated its U.S. distribution...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Anika Therapeutics Terminates Contract with U.S. Distribution Partner for ELEVESS]]></title>
<link>http://www.Dzugg.com/WeightLoss/Anika_Therapeutics_Terminates_Contract_with_U-S-_Distribution_Partner_for_ELEVESS/</link>
<comments>http://www.Dzugg.com/WeightLoss/Anika_Therapeutics_Terminates_Contract_with_U-S-_Distribution_Partner_for_ELEVESS/</comments>
<pubDate>Fri, 28 Nov 2008 02:50:35 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Anika_Therapeutics_Terminates_Contract_with_U-S-_Distribution_Partner_for_ELEVESS/</guid>
<description><![CDATA[BEDFORD, Mass.--(BUSINESS WIRE)--Nov 25, 2008 - Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (&amp;ldquo;HA&amp;rdquo;) technology, has terminated its U.S. distribution...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Antitrust: European Commission Confirms Unannounced Inspections at Pharmaceutical Companies]]></title>
<link>http://www.Dzugg.com/WeightLoss/Antitrust_European_Commission_Confirms_Unannounced_Inspections_at_Pharmaceutical_Companies/</link>
<comments>http://www.Dzugg.com/WeightLoss/Antitrust_European_Commission_Confirms_Unannounced_Inspections_at_Pharmaceutical_Companies/</comments>
<pubDate>Fri, 28 Nov 2008 02:49:42 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Antitrust_European_Commission_Confirms_Unannounced_Inspections_at_Pharmaceutical_Companies/</guid>
<description><![CDATA[BRUSSELS, Nov. 25, 2008-The European Commission can confirm that on 24 November Commission officials started inspections in several Member States at the premises of a number of pharmaceutical companies. The Commission has reason to believe that the.<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr]]></title>
<link>http://www.Dzugg.com/WeightLoss/Watson_Enters_Into_Agreement_to_Acquire_Products_Related_to_Tevas_Proposed_Acquisition_of_Barr/</link>
<comments>http://www.Dzugg.com/WeightLoss/Watson_Enters_Into_Agreement_to_Acquire_Products_Related_to_Tevas_Proposed_Acquisition_of_Barr/</comments>
<pubDate>Fri, 28 Nov 2008 02:47:55 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Watson_Enters_Into_Agreement_to_Acquire_Products_Related_to_Tevas_Proposed_Acquisition_of_Barr/</guid>
<description><![CDATA[CORONA, Calif., November 25, 2008 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals]]></title>
<link>http://www.Dzugg.com/WeightLoss/Roche_Signs_Definitive_Agreement_to_Acquire_Memory_Pharmaceuticals/</link>
<comments>http://www.Dzugg.com/WeightLoss/Roche_Signs_Definitive_Agreement_to_Acquire_Memory_Pharmaceuticals/</comments>
<pubDate>Fri, 28 Nov 2008 02:44:09 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Roche_Signs_Definitive_Agreement_to_Acquire_Memory_Pharmaceuticals/</guid>
<description><![CDATA[NUTLEY, N.J. and MONTVALE, N.J., Nov. 25 /PRNewswire-FirstCall/ -- Roche and Memory Pharmaceuticals today announced that the two companies have signed a definitive merger agreement for Roche to acquire all the outstanding shares of Memory...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca Provides Update on Agreement with Abraxis Biosciences for Co-Promotion of Abraxane in the US]]></title>
<link>http://www.Dzugg.com/WeightLoss/AstraZeneca_Provides_Update_on_Agreement_with_Abraxis_Biosciences_for_Co-Promotion_of_Abraxane_in_the_US/</link>
<comments>http://www.Dzugg.com/WeightLoss/AstraZeneca_Provides_Update_on_Agreement_with_Abraxis_Biosciences_for_Co-Promotion_of_Abraxane_in_the_US/</comments>
<pubDate>Fri, 28 Nov 2008 02:41:08 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/AstraZeneca_Provides_Update_on_Agreement_with_Abraxis_Biosciences_for_Co-Promotion_of_Abraxane_in_the_US/</guid>
<description><![CDATA[LONDON, Nov. 25, 2008-On 19 November 2008, AstraZeneca entered into an agreement with Abraxis BioScience, LLC, under which, subject to the satisfaction of terms and conditions thereof, Abraxis would re-acquire exclusive rights to market ABRAXANE in.<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Genzyme Seeks U.S. Approval for Clolar to Treat Adult AML]]></title>
<link>http://www.Dzugg.com/WeightLoss/Genzyme_Seeks_U-S-_Approval_for_Clolar_to_Treat_Adult_AML/</link>
<comments>http://www.Dzugg.com/WeightLoss/Genzyme_Seeks_U-S-_Approval_for_Clolar_to_Treat_Adult_AML/</comments>
<pubDate>Fri, 28 Nov 2008 02:41:00 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Genzyme_Seeks_U-S-_Approval_for_Clolar_to_Treat_Adult_AML/</guid>
<description><![CDATA[Indication Would Address Significant Unmet Medical Need and Expand Product UseCAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 24, 2008 - Genzyme Corporation (Nasdaq: GENZ) announced today that it has filed a supplemental New Drug Application with the U<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Anti-obesity agent Acomplia is withdrawn - Healthcare Republic]]></title>
<link>http://www.Dzugg.com/WeightLoss/Anti-obesity_agent_Acomplia_is_withdrawn_-_Healthcare_Republic/</link>
<comments>http://www.Dzugg.com/WeightLoss/Anti-obesity_agent_Acomplia_is_withdrawn_-_Healthcare_Republic/</comments>
<pubDate>Thu, 27 Nov 2008 17:19:09 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Anti-obesity_agent_Acomplia_is_withdrawn_-_Healthcare_Republic/</guid>
<description><![CDATA[Anti-obesity agent Acomplia is withdrawnHealthcare Republic&amp;nbsp;- 10 hours agoThe marketing authorisation for Acomplia (rimonabant) has been suspended after a European Medicines Agency (EMEA) review. The EMEA&amp;#39;s <br/><br/>101 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Schering-Plough Highlights R&amp;amp;D Pipeline Progress, Innovation and Breadth of Research Projects]]></title>
<link>http://www.Dzugg.com/WeightLoss/Schering-Plough_Highlights_RampD_Pipeline_Progress_Innovation_and_Breadth_of_Research_Projects/</link>
<comments>http://www.Dzugg.com/WeightLoss/Schering-Plough_Highlights_RampD_Pipeline_Progress_Innovation_and_Breadth_of_Research_Projects/</comments>
<pubDate>Wed, 26 Nov 2008 11:21:02 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Schering-Plough_Highlights_RampD_Pipeline_Progress_Innovation_and_Breadth_of_Research_Projects/</guid>
<description><![CDATA[KENILWORTH, N.J., November 24, 2008 /PRNewswire-FirstCall/ -- Leaders of Schering-Plough Corporation today provided an update for investors on the company's research pipeline, highlighting a rich and innovative portfolio that includes 46 new...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Lilly Completes Acquisition of ImClone Systems]]></title>
<link>http://www.Dzugg.com/WeightLoss/Lilly_Completes_Acquisition_of_ImClone_Systems/</link>
<comments>http://www.Dzugg.com/WeightLoss/Lilly_Completes_Acquisition_of_ImClone_Systems/</comments>
<pubDate>Wed, 26 Nov 2008 11:20:45 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Lilly_Completes_Acquisition_of_ImClone_Systems/</guid>
<description><![CDATA[INDIANAPOLIS, Nov. 24 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it has completed its acquisition of ImClone Systems Incorporated. ImClone Systems is now a wholly-owned subsidiary of Lilly.&quot;We are excited about the...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[XDx Announces Strategic Restructuring]]></title>
<link>http://www.Dzugg.com/WeightLoss/XDx_Announces_Strategic_Restructuring/</link>
<comments>http://www.Dzugg.com/WeightLoss/XDx_Announces_Strategic_Restructuring/</comments>
<pubDate>Wed, 26 Nov 2008 11:20:21 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/XDx_Announces_Strategic_Restructuring/</guid>
<description><![CDATA[BRISBANE, Calif.--(BUSINESS WIRE)--Nov 24, 2008 - XDx, a molecular diagnostic company based in Brisbane, California, announced today that it is restructuring its business. In response to current market conditions, XDx is reprioritizing its efforts..<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA Extends Review of Somaxon Pharmaceuticals' New Drug Application for Silenor (Doxepin) by up to Three Months]]></title>
<link>http://www.Dzugg.com/WeightLoss/FDA_Extends_Review_of_Somaxon_Pharmaceuticals_New_Drug_Application_for_Silenor_Doxepin_by_up_to_Three_Months/</link>
<comments>http://www.Dzugg.com/WeightLoss/FDA_Extends_Review_of_Somaxon_Pharmaceuticals_New_Drug_Application_for_Silenor_Doxepin_by_up_to_Three_Months/</comments>
<pubDate>Wed, 26 Nov 2008 11:19:52 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/FDA_Extends_Review_of_Somaxon_Pharmaceuticals_New_Drug_Application_for_Silenor_Doxepin_by_up_to_Three_Months/</guid>
<description><![CDATA[Conference call scheduled today at 6 a.m. PT; Simultaneous webcast at http://investors.somaxon.com/eventdetail.cfm&amp;nbsp;SAN DIEGO--(BUSINESS WIRE)--Nov 24, 2008 - Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical co<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion]]></title>
<link>http://www.Dzugg.com/WeightLoss/King_Pharmaceuticals_To_Acquire_Alpharma_for_Approximately_1-6_Billion/</link>
<comments>http://www.Dzugg.com/WeightLoss/King_Pharmaceuticals_To_Acquire_Alpharma_for_Approximately_1-6_Billion/</comments>
<pubDate>Wed, 26 Nov 2008 11:17:56 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/King_Pharmaceuticals_To_Acquire_Alpharma_for_Approximately_1-6_Billion/</guid>
<description><![CDATA[&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;BRISTOL, Tenn. and BRIDGEWATER, N.J., November 24, 2008 /PRNewswire-FirstCall/ -- King Pharmaceuticals, Inc. and Alpharma Inc. today announced that the two companies have signed a definitive merger agr<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[PhRMA Statement on New National Advertising Campaign]]></title>
<link>http://www.Dzugg.com/WeightLoss/PhRMA_Statement_on_New_National_Advertising_Campaign/</link>
<comments>http://www.Dzugg.com/WeightLoss/PhRMA_Statement_on_New_National_Advertising_Campaign/</comments>
<pubDate>Wed, 26 Nov 2008 11:17:52 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/PhRMA_Statement_on_New_National_Advertising_Campaign/</guid>
<description><![CDATA[WASHINGTON, November 14, 2008 &amp;mdash; Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin issued the following statement today:&amp;ldquo;Starting Monday, PhRMA will launch a new advertising campaign pointin<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Johnson &amp;amp; Johnson Announces Definitive Agreement to Acquire Omrix]]></title>
<link>http://www.Dzugg.com/WeightLoss/Johnson_amp_Johnson_Announces_Definitive_Agreement_to_Acquire_Omrix/</link>
<comments>http://www.Dzugg.com/WeightLoss/Johnson_amp_Johnson_Announces_Definitive_Agreement_to_Acquire_Omrix/</comments>
<pubDate>Wed, 26 Nov 2008 11:16:18 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Johnson_amp_Johnson_Announces_Definitive_Agreement_to_Acquire_Omrix/</guid>
<description><![CDATA[&amp;nbsp;&amp;nbsp;NEW BRUNSWICK, N.J. and NEW YORK, November 24, 2008 /PRNewswire-FirstCall/ -- Johnson &amp;amp; Johnson and Omrix Biopharmaceuticals, Inc. , a fully integrated biopharmaceutical company that develops and markets biosurgical and..<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Labopharm's NDA for Novel Trazodone Formulation Accepted for Review by FDA]]></title>
<link>http://www.Dzugg.com/WeightLoss/Labopharms_NDA_for_Novel_Trazodone_Formulation_Accepted_for_Review_by_FDA/</link>
<comments>http://www.Dzugg.com/WeightLoss/Labopharms_NDA_for_Novel_Trazodone_Formulation_Accepted_for_Review_by_FDA/</comments>
<pubDate>Wed, 26 Nov 2008 11:15:30 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Labopharms_NDA_for_Novel_Trazodone_Formulation_Accepted_for_Review_by_FDA/</guid>
<description><![CDATA[- Action Date is July 18, 2009 -LAVAL, QC, November 24, 2008 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagon<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes]]></title>
<link>http://www.Dzugg.com/WeightLoss/New_Data_Advanced_Pharmacy_Model_Significantly_Reduces_Gaps_in_Care_for_Patients_with_Chronic_and_Complex_Conditions_Improves_Clinical_and_Financial_Outcomes/</link>
<comments>http://www.Dzugg.com/WeightLoss/New_Data_Advanced_Pharmacy_Model_Significantly_Reduces_Gaps_in_Care_for_Patients_with_Chronic_and_Complex_Conditions_Improves_Clinical_and_Financial_Outcomes/</comments>
<pubDate>Wed, 26 Nov 2008 11:12:57 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/New_Data_Advanced_Pharmacy_Model_Significantly_Reduces_Gaps_in_Care_for_Patients_with_Chronic_and_Complex_Conditions_Improves_Clinical_and_Financial_Outcomes/</guid>
<description><![CDATA[FRANKLIN LAKES, N.J., November 21, 2008 /PRNewswire-FirstCall/ -- Today, prescription drugs are the first choice for medical intervention in treating 88 percent of patients suffering chronic conditions. The 50 percent of Americans treated for a...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Firm stops trials of obesity drug - Healthcare Republic]]></title>
<link>http://www.Dzugg.com/WeightLoss/Firm_stops_trials_of_obesity_drug_-_Healthcare_Republic/</link>
<comments>http://www.Dzugg.com/WeightLoss/Firm_stops_trials_of_obesity_drug_-_Healthcare_Republic/</comments>
<pubDate>Wed, 26 Nov 2008 04:34:28 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Firm_stops_trials_of_obesity_drug_-_Healthcare_Republic/</guid>
<description><![CDATA[Firm stops trials of obesity drugHealthcare Republic&amp;nbsp;- Nov 13, 2008Sanofi-Aventis has discontinued all trials of its anti-obesity drug rimonabant (Acomplia), which was suspended by the European Medicines Agency <br/><br/>101 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Barr Shareholders Approve Pending Teva Acquisition]]></title>
<link>http://www.Dzugg.com/WeightLoss/Barr_Shareholders_Approve_Pending_Teva_Acquisition/</link>
<comments>http://www.Dzugg.com/WeightLoss/Barr_Shareholders_Approve_Pending_Teva_Acquisition/</comments>
<pubDate>Tue, 25 Nov 2008 17:47:45 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Barr_Shareholders_Approve_Pending_Teva_Acquisition/</guid>
<description><![CDATA[MONTVALE, N.J., November 21, 2008 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that its shareholders overwhelmingly approved the proposals submitted to them relating to the acquisition of Barr by Teva Pharmaceuticals...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[High Growth Reported for the World Smoking Cessation Aids Market - Business Wire (press release)]]></title>
<link>http://www.Dzugg.com/WeightLoss/High_Growth_Reported_for_the_World_Smoking_Cessation_Aids_Market_-_Business_Wire_press_release/</link>
<comments>http://www.Dzugg.com/WeightLoss/High_Growth_Reported_for_the_World_Smoking_Cessation_Aids_Market_-_Business_Wire_press_release/</comments>
<pubDate>Tue, 25 Nov 2008 11:00:15 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/High_Growth_Reported_for_the_World_Smoking_Cessation_Aids_Market_-_Business_Wire_press_release/</guid>
<description><![CDATA[High Growth Reported for the World Smoking Cessation Aids MarketBusiness Wire (press release),&amp;nbsp;CA&amp;nbsp;- 5 hours agoProduct Innovations/Introductions II-20 Acomplia to Enter Smoking Cessation Market II-20 Fertin<br/><br/>101 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Physicians Anticipate Higher Prescribing Based on JUPITER Study]]></title>
<link>http://www.Dzugg.com/WeightLoss/Physicians_Anticipate_Higher_Prescribing_Based_on_JUPITER_Study/</link>
<comments>http://www.Dzugg.com/WeightLoss/Physicians_Anticipate_Higher_Prescribing_Based_on_JUPITER_Study/</comments>
<pubDate>Mon, 24 Nov 2008 20:48:36 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Physicians_Anticipate_Higher_Prescribing_Based_on_JUPITER_Study/</guid>
<description><![CDATA[SAN MATEO, Calif., November 21, 2008 /PRNewswire/ -- Just three days after the JUPITER trial results were presented at the American Heart Association meeting and simultaneously published online by the New England Journal of Medicine, an AlphaDetail.<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[CHMP Posts 12 Opinions]]></title>
<link>http://www.Dzugg.com/WeightLoss/CHMP_Posts_12_Opinions/</link>
<comments>http://www.Dzugg.com/WeightLoss/CHMP_Posts_12_Opinions/</comments>
<pubDate>Mon, 24 Nov 2008 20:48:14 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/CHMP_Posts_12_Opinions/</guid>
<description><![CDATA[LONDON, Nov. 20, 2008-The CHMP today posted on its website opinions for&amp;nbsp;12 drugs. Links to the opinions are below.Committee for Medicinal Products for Human Use Post-Authorisation Summary of Positive Opinion for EnbrelLONDON, Nov. 2<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[MINRAD International, Inc. Announces Reduction in Workforce]]></title>
<link>http://www.Dzugg.com/WeightLoss/MINRAD_International_Inc-_Announces_Reduction_in_Workforce/</link>
<comments>http://www.Dzugg.com/WeightLoss/MINRAD_International_Inc-_Announces_Reduction_in_Workforce/</comments>
<pubDate>Mon, 24 Nov 2008 20:48:01 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/MINRAD_International_Inc-_Announces_Reduction_in_Workforce/</guid>
<description><![CDATA[ORCHARD PARK, N.Y., November 20, 2008 /PRNewswire-FirstCall/ -- MINRAD International, Inc. , announced effective today it will reduce its workforce by approximately 35% or 50 positions.&amp;nbsp;Dave DiGiacinto, President and Chief Operating<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Nplate (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union]]></title>
<link>http://www.Dzugg.com/WeightLoss/Nplate_Romiplostim_Receives_Positive_Opinion_for_Marketing_Authorisation_in_the_European_Union/</link>
<comments>http://www.Dzugg.com/WeightLoss/Nplate_Romiplostim_Receives_Positive_Opinion_for_Marketing_Authorisation_in_the_European_Union/</comments>
<pubDate>Mon, 24 Nov 2008 20:47:45 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Nplate_Romiplostim_Receives_Positive_Opinion_for_Marketing_Authorisation_in_the_European_Union/</guid>
<description><![CDATA[First and Only Approved Platelet Producer Represents New Treatment Approach for Serious Chronic Autoimmune DisorderTHOUSAND OAKS, Calif., November 21, 2008 /PRNewswire-FirstCall/ -- Amgen today announced that the European Committee for Medicin<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Lilly Completes Cash Tender Offer for ImClone Systems]]></title>
<link>http://www.Dzugg.com/WeightLoss/Lilly_Completes_Cash_Tender_Offer_for_ImClone_Systems/</link>
<comments>http://www.Dzugg.com/WeightLoss/Lilly_Completes_Cash_Tender_Offer_for_ImClone_Systems/</comments>
<pubDate>Mon, 24 Nov 2008 20:47:02 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/Lilly_Completes_Cash_Tender_Offer_for_ImClone_Systems/</guid>
<description><![CDATA[INDIANAPOLIS and New York, November 21, 2008 /PRNewswire-FirstCall/ -- Eli Lilly and Company and ImClone Systems Incorporated today announced the successful completion of the previously announced tender offer by Lilly's wholly-owned subsidiary,...<br/><br/>15 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[CombinatoRx Concentrates on Core Strengths]]></title>
<link>http://www.Dzugg.com/WeightLoss/CombinatoRx_Concentrates_on_Core_Strengths/</link>
<comments>http://www.Dzugg.com/WeightLoss/CombinatoRx_Concentrates_on_Core_Strengths/</comments>
<pubDate>Mon, 24 Nov 2008 20:46:29 PST</pubDate>
<dc:creator></dc:creator>
<category>WeightLoss</category>
<guid>http://www.Dzugg.com/WeightLoss/CombinatoRx_Concentrates_on_Core_Strengths/</guid>
<description><![CDATA[CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 20, 2008 - CombinatoRx, Incorporated (NASDAQ: CRXX) today announced a further restructuring, effective immediately, to focus on the core strength of the company: identifying novel product candidates based on...<br/><br/>15 Vote(s) ]]></description>
</item>

</channel>
</rss>
